Piper Jaffray downgrades ACADIA Pharmaceuticals (Nasdaq: ACAD) from Buy to Neutral and lowers its price target from $6 to $3.
This article: 101 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE